Abstract:Objective: To investigate the effects of miRNA-mediated down-regulation of the Bcl-2 gene on the chemotherapeutic sensitivities and mRNA transcriptions of sensitivity associated genes in human lung adenocarcinoma cell line A549 cells, and therefore to provide experimental data for improving the chemotherapeutic effects on non-small cell lung cancer (NSCLC). Methods: The miRNA recombinant plasmid targeting to human Bcl-2 gene was designed, synthesized and stably transferred into A549 cells by lipofectin technique as the experiment group. The transcription of Bcl-2 mRNA was detected by reverse transcription-polymerase chain reaction (RT-PCR) by agarose gel electrophoresis, real-time PCR, and the protein level of Bcl-2 was measured by Western blot to confirm the function of miRNA plasmid. The cell proliferation was examined by methyl thiazolyl tetrazolium (MTT) assay. Cell cycle was measured by flow cytometry. Drug sensitivities of A549 cells to etoposide, 5-fluorouracil, cisplatin, adriamycin, vincristine, paclitaxel and navelbine were analyzed by MTT assay. The mRNA expressions of excision repair cross-complementing gene 1 (ERCC1), thymidylate synthase (TYMS), Class III β-tubulin, topoisomerase 2 alpha (TOP2α) genes were detected by RT-PCR and real-time PCR. Results: The recombinant miRNA plasmid was successfully synthesized and stably transferred into A549 cells. The transcription of Bcl-2 mRNA dramatically decreased by 98.1% in the experiment group (RQ = 0.002 ± 0.001) compared to that in the negative control group (RQ = 0.104 ± 0.003) by real-time PCR (t = 98.70, P < 0.05); and the protein level of Bcl-2 in the experiment group decreased by 57.6% by Western blot (t = 7.66, P < 0.05). The cell cycle profile showed that the low expression of Bcl-2 gene led to A549 cell cycle arrest at G1-phase. The results of MTT showed that the growth of A549 cells in the experiment group was markedly inhibited. The sensitivities of A549 cells to etoposide, cisplatin, paclitaxel, and navelbine were significantly enhanced [IC₅₀ values in the experiment group were (107.3 ± 0.1) mg/L, (7.7 ± 0.6) mg/L, (11.5 ± 1.9) mg/L and (10.8 ± 1.6) mg/L; IC₅₀ values in the negative control group were (145.8 ± 0.1) mg/L, (60.7 ± 1.4) mg/L, (80.6 ± 1.7) mg/L and (20.6 ± 1.7) mg/L], the respective t values being 655.33, 108.04, 82.16 and 12.48, all P < 0.05. The mRNA level of ERCC1, TYMS, and TOP2α genes in the experiment group decreased by 99.6%, 92.9% and 96.1% respectively, but Class III β-tubulin mRNA increased by 122% compared to the negative control group (1.154 ± 0.008, 0.520 ± 0.009), the respective t values being 689.79, 689.37, 768.04 and 160.07, all P < 0.05. Conclusion: Targeting to inhibit antiapoptotic mitochondrial gene Bcl-2 expression in A549 cells specifically decreased the mRNA of ERCC1, TYMS, and TOP2α genes, and significantly increased the sensitivities of A549 cells to chemotherapeutic agents such as etoposide, cisplatin, paclitaxel and navelbine.

[Design of Antisense Oligodeoxynucleotide Targeting at Bcl-2 Mrna and Observation on Its Effect on the Sensitivity of Leukemia Cells to Arabinosyl Cytosine].

PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

Antisense C - Myc Sensitizes Osteosarcoma Cells to Cisplatin- Induced Apoptosis

Bcl-2 antisense oligodeoxynucleotides to enhance the apoptosis-inducing effect of artesunate on K562 cells

Study on antisense oligoncleotides as inhibitor of human acute promyelocytic leukemia proliferation and protein expression

Structural Optimization and Additional Targets Identification of Antisense Oligonucleotide G3139 Encapsulated in a Neutral Cytidinyl-Lipid Combined with a Cationic Lipid in Vitro and in Vivo

[Effects of Bcl-2 Antisense Oligodeoxynucleotide on Proliferation and Apoptosis of Human Melanoma A375 Cell Line].

Asymmetric Sirna Targeting The Bcl-2 Gene Inhibits The Proliferation Of Cancer Cells In Vitro And In Vivo

Inhibition of P-glycoprotein and increasing of drug-sensitivity of a human carcinoma cell line (KB-A-1) by an antisense oligodeoxynucleotide-doxorubicin conjugate in vitro.

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

[The Effects of Antisense Oligonucleotides Bcl-2/Bcl-xl and Bcl-2 on Proliferation and Apoptosis of Breast Cancer Cells].

Antisense Oligonucleotide Targeting Survivin Induces Apoptosis of SMMC-7721 Cell and Enhances Its Sensitivity to Chemotherapeutic Agents in Vitro

Caspase-3 antisense oligodeoxynucleotides inhibit apoptosis in γ-irradiated human leukemia HL-60 cells

Caspase-3 antisense oligodeoxynucleotides inhibit apoptosis in gamma-irradiated human leukemia HL-60 cells.

Study on the Effects of C-Erbb-2-specific Antisense Oligonucleotides on C-Erbb-2 Overexpressing Breast Cancer Cells

[The Toxic Effects of High-Dose Bcl-2 Antisense Phosphorothioate Oligodeoxynucleotides Incubation on Cell Line].

Regulating Gene Expression in Human Leukemia Cells Using Light-Activated Oligodeoxynucleotides.

Cancer-cell-membrane-camouflaged Supramolecular Self-Assembly of Antisense Oligonucleotide and Chemodrug for Targeted Combination Therapy

A preliminary study of AS1411 mediated STAT3 antisense oligonucleotide targeting tumor cells

RNA interference remarkably suppresses bcl-2 gene expression in cancer cells in vitro and in vivo.

[The effect of Bcl-2 gene silencing on the sensitivity of cell line A549 to chemotherapeutic drugs]